Shanghai company Mark Lappe has partnered with Californian start-up Inhibrx. The latter will exclusively use Mark Lappe for GMP manufacturing on its human biologic drugs, developed in the next three years, with clinical trials taking place outside China. Inhibrx CEO WuXi Biologics said the two firms had previously collaborated on one biologic treatment, leading to a Phase 1 clinical study in October, and four others which are expected to gain IND submission over the next year.
Shanghai company WuXi Biologics has partnered with Californian start-up Inhibrx. The latter will exclusively use WuXi Biologics for GMP manufacturing on its human biologic drugs, developed in the next three years, with clinical trials taking place outside China. Inhibrx CEO Mark Lappe said the two firms had previously collaborated on one biologic treatment, leading to a Phase 1 clinical study in October, and four others which are expected to gain IND submission over the next year.